The FDA has approved bosulif (bosutinib) for patients aged 1 year or older with chronic phase Ph+ CML.
Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
Lymphoma patients who receive high-dose chemotherapy and autologous HSCT have an increased risk of second primary malignancies, data suggest.
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Aphexda (motixafortide) is expected to be available later this month.
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
Loncastuximab tesirine produced durable responses in a phase 2 trial of patients with relapsed or refractory DLBCL.
The combination of oral mezigdomide and dexamethasone has shown activity in patients with relapsed/refractory multiple myeloma.
About 1 in 5 immunosuppressed individuals have no detectable IgG anti-spike antibodies after 3 or more COVID-19 vaccinations, a new study suggests.
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations.
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.
Bexmarilimab is a first-in-class, humanized monoclonal antibody designed to target Clever-1, a receptor on macrophages that leads to tumor growth and metastasis.